Financial Review: Cardiome Pharma Corporation (CRME) and Its Peers
Cardiome Pharma Corporation (NASDAQ: CRME) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it contrast to its rivals? We will compare Cardiome Pharma Corporation to related companies based on the strength of its analyst recommendations, risk, institutional ownership, valuation, earnings, dividends and profitability.
Insider and Institutional Ownership
55.1% of Cardiome Pharma Corporation shares are owned by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 13.9% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This table compares Cardiome Pharma Corporation and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cardiome Pharma Corporation||-110.95%||-78.51%||-38.30%|
|Cardiome Pharma Corporation Competitors||-13,073.01%||230.26%||-22.81%|
This is a breakdown of recent ratings and recommmendations for Cardiome Pharma Corporation and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cardiome Pharma Corporation||0||1||4||0||2.80|
|Cardiome Pharma Corporation Competitors||190||909||1681||67||2.57|
Cardiome Pharma Corporation presently has a consensus price target of $6.56, suggesting a potential upside of 180.45%. As a group, “Biopharmaceuticals” companies have a potential upside of 2.12%. Given Cardiome Pharma Corporation’s stronger consensus rating and higher possible upside, research analysts clearly believe Cardiome Pharma Corporation is more favorable than its rivals.
Volatility and Risk
Cardiome Pharma Corporation has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Cardiome Pharma Corporation’s rivals have a beta of 1.24, indicating that their average share price is 24% more volatile than the S&P 500.
Earnings & Valuation
This table compares Cardiome Pharma Corporation and its rivals revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Cardiome Pharma Corporation||$23.21 million||-$17.41 million||-2.82|
|Cardiome Pharma Corporation Competitors||$578.59 million||$241.91 million||-6.43|
Cardiome Pharma Corporation’s rivals have higher revenue and earnings than Cardiome Pharma Corporation. Cardiome Pharma Corporation is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Cardiome Pharma Corporation rivals beat Cardiome Pharma Corporation on 7 of the 12 factors compared.
Cardiome Pharma Corporation Company Profile
Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.
Receive News & Ratings for Cardiome Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.